Anecdotal feedback from secondaries professionals reveals a quick onset of stagnation in the market due to COVID-19. Creative workarounds are not impossible, but almost
There are two main channels of secondaries deal flow: hot tickets in the form desirable fund positions and portfolio companies where new investors clamor for exposure and the various situations where existing...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.